Inclusion Criteria
	Metastatic melanoma or non-squamous NSCLC with untreated brain metastases
	Biopsy proven metastatic melanoma or non-squamous NSCLC with at least one untreated cerebral metastasis that is at least 5 mm AND twice the magnetic resonance imaging (MRI) slice thickness, but less than 20 mm, that is asymptomatic and does not require local therapy at the time of enrollment (â€œclinically evaluable lesion[s]â€); an untreated brain metastasis is defined as a lesion not present at the time of whole brain radiation therapy or included in a stereotactic radiotherapy field (or within 2 mm of a treated lesion), or any lesion that is new or unequivocally progressing since prior radiation therapy; all MRIs at screening will be reviewed centrally at Yale for sign off of eligibility 
	Age >= 18 
	Eastern Cooperative Oncology Group (ECOG) performance status < 2
	Any number of previous treatments with the exception of previous inhibitors of programmed cell death 1 (PD-1), PD-L1, or programmed cell death 1 ligand 2 (PD-L2); other prior systemic therapies must have been administered at least 2 weeks before administration of pembrolizumab; the exception to this is ipilimumab which must have been administered at least 4 weeks prior to the start of pembrolizumab; patients are not required to have had prior systemic therapy

Exclusion Criteria
	Symptomatic brain metastases; any neurologic symptoms present must have resolved with local therapy by the time of administration of study drug 
	Patients with brain metastases for whom complete surgical resection is clinically appropriate 
	Patients with lung cancer with squamous histology
	Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to start of treatment or has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; previous radiation to extracranial sites may be completed at any time prior to initiation of pembrolizumab;
•	Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
•	Note: Toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters 
	Has had prior treatment with any other anti-PD-1 or PD-L1 or PD-L2 agent
